Erlocip 150 MG Tablet contains Erlotinib 150mg in an alternative brand formulation, delivering the same reversible EGFR inhibition for EGFR mutation-positive non-small cell lung cancer treatment.

How It Works: Erlotinib occupies the ATP-binding site on the EGFR intracellular domain, preventing kinase activation and blocking the downstream RAS-MAPK and PI3K signaling cascades that sustain EGFR-mutant tumors.

Common Uses: EGFR exon 19 deletion or L858R mutation-positive NSCLC, maintenance NSCLC therapy, and advanced pancreatic cancer in combination with gemcitabine.

Administration: Take once daily on an empty stomach. Consistent fasted administration improves bioavailability and therapeutic consistency. Swallow whole with water.

Storage: Store below 25°C in a dry place. Keep in original packaging away from moisture and children.

Disclaimer: This product requires a valid prescription. Consult a licensed oncologist before use. This information is for educational purposes only.